Last10K.com

Ekimas Corp (ASNB) SEC Filing 8-K Material Event for the period ending Monday, April 17, 2023

Advansource Biomaterials Corp

HISTORY TOOLS
CIK: 1499961 Ticker: ASNB

View differences made from one to another to evaluate Advansource Biomaterials Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Advansource Biomaterials Corp.

Continue

Assess how Advansource Biomaterials Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Advansource Biomaterials Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Cover

Material Contracts, Statements, Certifications & more

Advansource Biomaterials Corp provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract
Exhibit 10.2: Material Contract
Ticker: ASNB
CIK: 1011060
Form Type: 8-K Corporate News
Accession Number: 0001493152-23-015277
Submitted to the SEC: Wed May 03 2023 12:19:01 PM EST
Accepted by the SEC: Wed May 03 2023
Period: Monday, April 17, 2023
Industry: Surgical And Medical Instruments And Apparatus
Events:
  1. Event for Officers
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/asnb/0001493152-23-015277.htm